Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)



Status:Active, not recruiting
Conditions:Cognitive Studies, Other Indications
Therapuetic Areas:Psychiatry / Psychology, Other
Healthy:No
Age Range:40 - 65
Updated:3/8/2019
Start Date:October 1, 2013
End Date:March 31, 2019

Use our guide to learn which trials are right for you!

This study will investigate the use of adjunctive pregnenolone for the following:

1. fatigue that has limited usual activity,

2. musculoskeletal pain involving 2 or more regions of the body and,

3. cognitive symptoms (memory, concentration, or attentional difficulties by self-report)
in Veterans deployed to the Gulf War theatre of operations between 1990 and 1991.


Inclusion Criteria:

- Veterans deployed to the Gulf War theatre of operations between 1990 and 1991.

- Veterans who report at least 2 of the following 3 symptoms that began in 1990 or
thereafter, that lasted for more than 6 months, and that are present at the time of
screening: 1) fatigue that limited usual activity, 2) musculoskeletal pain involving 2
or more regions of the body, 3) cognitive symptoms (memory, concentration, or
attentional difficulties by self-report)

- Stable on medication regimen (no change in last 4 weeks) and no anticipated change in
medication during study.

- Able to provide informed consent for study participation.

Exclusion Criteria:

- Subjects with a history of clinically significant neurological, metabolic, hepatic,
renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological
disorders (e.g. unstable angina, seizures, cerebrovascular accident, decompensated
congestive heart failure, central nervous system (CNS) infection, cancer [other than
non-melanoma skin cancer], or history of HIV seropositivity), which would pose a risk
to the patient if s/he were to participate in the study or that might confound the
results of the study.

- Concurrent enrollment in another clinical trial.

- Pregnant women or women of child-bearing potential who are not surgically-sterile or
not using appropriate methods of birth control.

- Use of oral contraceptives or other hormonal supplementation such as estrogen
[although early studies suggested no effects on menstrual cycle, alterations in
downstream metabolites or pregnenolone (such as estradiol) could theoretically impact
the efficacy or oral contraceptives and/or estrogen replacement]. Similarly, it is
theoretically possible that pregnenolone could be metabolized to other steroids such a
DHEA, potentially resulting in hair, skin, or other steroid-related changes. Since the
investigators' have determined in their prior study that pregnenolone administration
does not result in downstream elevations in DHEA, DHEAS, estradiol, or testosterone,
these possibilities may be unlikely.

- Women who are breast-feeding.

- Use of narcotic interventions.

- Known allergy to study medication.

- History of moderate or severe TBI (with loss of consciousness greater than 30 minutes)

- A clearly defined disease entity that accounts for the Veteran's symptoms.

- Current DSM-IV/DSM-IVTR/DSM-V diagnosis of bipolar I disorder, schizophrenia or other
psychotic disorder, or dementia.

- Subjects with a DSM-IV/DSM-IVTR/DSM-V diagnosis of alcohol or substance dependence
(other than nicotine or caffeine) within the last month.

- Subjects with a current suicidal or homicidal ideation necessitating clinical
intervention or representing an imminent concern.

- If in the judgment of the PI it is not in the subject's best interest to participate.

- Final eligibility decisions will be determined by the PI.
We found this trial at
1
site
Durham, North Carolina 27705
Principal Investigator: Christine Marx, MD MA
Phone: 919-286-0411
?
mi
from
Durham, NC
Click here to add this to my saved trials